Theralase Technologies Inc.
TLT.V
TSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -41.11% | -20.20% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -41.11% | -20.20% | |||
| Cost of Revenue | 611.59% | -92.13% | |||
| Gross Profit | -70.17% | 34.61% | |||
| SG&A Expenses | -7.25% | 8.27% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 26.94% | -30.18% | |||
| Operating Income | -49.18% | 32.93% | |||
| Income Before Tax | -50.85% | 33.06% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -50.85% | 33.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -50.85% | 33.06% | |||
| EBIT | -49.18% | 32.93% | |||
| EBITDA | -54.99% | 34.96% | |||
| EPS Basic | -47.37% | 34.48% | |||
| Normalized Basic EPS | -41.67% | 33.33% | |||
| EPS Diluted | -47.37% | 34.48% | |||
| Normalized Diluted EPS | -41.67% | 33.33% | |||
| Average Basic Shares Outstanding | 1.75% | 4.01% | |||
| Average Diluted Shares Outstanding | 1.75% | 4.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||